Symbols

DERM

Journey Medical·NASDAQ

--(--)

DERM fundamentals

DERM Q4 2025 Earnings

Journey Medical (DERM) released its earnings on Mar 25, 2026: revenue was 16.08M (YoY +18.11%), missed estimates; EPS was -0.54 (YoY -640.00%), missed estimates.

Revenue / YoY

16.08M

+18.11%

EPS / YoY

-0.54

-640.00%

Report date

Mar 25, 2026

DERM Earnings Call Summary for Q4,2025

EMROSI Dominance: 2025 sales of $14.7M, 53,000 prescriptions, and 27,000 Q4 scripts highlight strong adoption. Q1 2026 scripts expected to surpass Q4 2025.
Financial Turnaround: 11% revenue growth, 3.5% gross margin improvement, and positive EBITDA in Q4 2025. Cash position of $24M supports expansion.
Market Access Expansion: 100M commercial lives covered, 3,500+ prescribers, and Q2 2026 GPO signings to drive reimbursement improvements.
Pipeline Momentum: Two new dermatology products set to launch in 2026, targeting $6M annual rosacea prescription market.

Earnings

EPS

Revenue

Revenue & Expenses

DERM has released its 2025 Q3 earnings report, with revenue of 17.63M, reflecting a YoY change of 20.52%, and net profit of -2.31M, showing a YoY change of 3.14%. The Sankey diagram below clearly presents DERM's revenue sources and cost distribution.

Key Indicators

Journey Medical (DERM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Journey Medical (DERM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Journey Medical (DERM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Journey Medical (DERM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown